Clinical Trial Update: Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating sitagliptin for reactive hypoglycemia due to dysinsulinism has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Reactive Hypoglycemia

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: Reactive Hypoglycemia | Phase 4 | Status: COMPLETED